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Abstract
Background: The United States is in an opioid epidemic. Passive decision support in the electronic health record (EHR) through
opioid prescription presets may aid in curbing opioid dependence.
Objective: The objective of this study is to determine whether modification of opioid prescribing presets in the EHR could
change prescribing patterns for an entire hospital system.
Methods: We performed a quasi-experimental retrospective pre–post analysis of a 24-month period before and after modifications
to our EHR’s opioid prescription presets to match Centers for Disease Control and Prevention guidelines. We included all opioid
prescriptions prescribed at our institution for nonchronic pain. Our modifications to the EHR include (1) making duration of
treatment for an opioid prescription mandatory, (2) adding a quick button for 3 days’ duration while removing others, and (3)
setting the default quantity of all oral opioid formulations to 10 tablets. We examined the quantity in tablets, duration in days,
and proportion of prescriptions greater than 90 morphine milligram equivalents/day for our hospital system, and compared these
values before and after our intervention for effect.
Results: There were 78,246 prescriptions included in our study written on 30,975 unique patients. There was a significant
reduction for all opioid prescriptions pre versus post in (1) the overall median quantity of tablets dispensed (54 [IQR 40-120] vs
42 [IQR 18-90]; P<.001), (2) median duration of treatment (10.5 days [IQR 5.0-30] vs 7.5 days [IQR 3.0-30]; P<.001), and (3)
proportion of prescriptions greater than 90 morphine milligram equivalents/day (27.46% [10,704/38,976; 95% CI 27.02%-27.91%]
vs 22.86% [8979/39,270; 95% CI 22.45%-23.28%]; P<.001).
Conclusions: Modifications of opioid prescribing presets in the EHR can improve prescribing practice patterns. Reducing
duration and quantity of opioid prescriptions could reduce the risk of dependence and overdose.
(J Med Internet Res 2021;23(4):e24360) doi: 10.2196/24360
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The opioid epidemic is a public health emergency unlike any
other [1-3]. The roots of this crisis are founded in over 30 years
of influential guidelines, marketing campaigns, and advertising
that led to an increase in opioid prescriptions [4-8].
Overprescribing has increased since the early 1990s [9]. In 2016,
there were 66.5 opioid prescriptions written for every 100
persons in the United States [10]. Prescription opioid abuse has
been associated with progression to use of heroin [11], and the
increased availability of both prescription and illicit opioids has
led to a rise in the rate of death [12]. Opioids caused over 67%
of drug-related deaths in 2017 and are responsible for nearly
400,000 deaths overall since 1999 [12].
Reductions in prescribing rates have become paramount to
combating the opioid epidemic. Higher doses and longer
durations of opioid therapy have been associated with an
increased risk of chronic opioid use, with a significant increase
in risk on treatment days 5 and 31 [13-15]. Therefore, the
Centers for Disease Control and Prevention (CDC) recommends
that caution be exercised when increasing doses to greater than
50 morphine milligram equivalents (MME) per day, and doses
greater than 90 MME/day should be avoided. The CDC also
states that 3 days or less is often sufficient for acute pain, and
more than 7 days is “rarely needed” [16,17].
The HITECH act of 2009 made electronic health records (EHRs)
ubiquitous. By 2017, 95% of hospitals in the United States are
using EHRs [18]. EHRs and the technologies associated with
them have been successfully utilized to combat the opioid
epidemic. Electronic prescribing of controlled substances can
improve medication safety, with a 2017 study demonstrating
that an increasing number of prescribers are prescribing
electronically [19]. Prescription drug monitoring programs,
which require prescribers to review prior controlled substance
prescriptions prior to prescribing, have shown reductions in
opioid prescribing rates [20]. Computerized provider order entry
(CPOE) systems are components of modern EHRs, and allow
for reduction in practice variation and medical error by
simplifying the prescribing of medications to an electronic
process [21].
In order to curb overprescribing and reduce quantities of tablets,
CPOE-linked interventions focus on preset defaulted
prescription settings [22-24]. Previous studies have shown that
the introduction or modification of opioid prescription presets
has demonstrated reductions of tablet quantities and prescription
MME for postsurgical patients [22], as well as significant
reductions in the number of tablet quantities dispensed in the
emergency department (ED) [23,25]. These studies suggest that
modification of EHR-linked CPOE settings is a simple,
inexpensive, and effective method of reducing the number of
tablets associated with opioid prescriptions. However, all
previous studies have focused on isolated emergency [23-27]
or surgery departments [22]. We are unaware of any research
examining the effects of modifications to opioid presets across
an entire hospital system.
Slovis et al [27] previously demonstrated a reduction in duration
of therapy and number of tablets dispensed when modifying
the opioid prescription presets in our ED [27]. The success of
this project prompted an enterprise-wide intervention to modify
opioid prescription settings in our EHR’s CPOE.
Our institution’s CPOE consists of 4 fields for oral tablet
prescription entry: (1) dose (number of tablets or milligrams
per dose), (2) frequency (doses per day), (3) duration (number
of days), and (4) quantity (number of tablets per prescription).
Prior to our intervention dose, frequency and quantity were
required for prescribing, but duration was not.
In August 2018, we implemented a number of interventions in
our EHR’s CPOE: (1) we made the duration of treatment for
an opioid prescription mandatory, (2) we provided a quick
button for 3 days’ duration on all opioid prescriptions while
removing all other quick buttons, and (3) we set the default
quantity to 10 tablets for all oral opioid formulations, and
removed any departmental variations. Prior to our intervention
there was variability in durations and quantity dispensed for
opioids (Multimedia Appendix 1). All interventions were passive
in nature, no decision support alerts were part of the design,
and there were no provider re-education measures nor large-scale
announcement as part of the implementation design.
The purpose of this study was to assess the effects of
modifications of opioid prescription default settings across an
entire institution. We hypothesize that modifications of these
settings can lead to reductions in duration of treatment, tablets
dispensed, and proportion of prescriptions greater than 90
MME/day for a hospital system for patients with nonchronic
pain. By demonstrating a reduction in prescribing at the hospital
system level we have the potential to reduce risk of dependence,
overdose, and possibly death.
Methods
Design, Setting, and Participants
In this quasi-experimental retrospective pre–post analysis, we
examined the effects on prescribing patterns at our institution
before and after modifications of opioid prescription settings.
Thomas Jefferson University Hospitals, as an enterprise, has
908 acute care beds and over 2700 physicians and practitioners
caring for more than 1.4 million people throughout the inpatient,
outpatient, and ED settings [28]. This study was performed at
the Center City Division, our urban academic institution
comprising a large tertiary-care hospital, a community hospital,
and multiple ambulatory clinics. Our study encompasses all
outpatient prescriptions for opioids written between September
1, 2017, and August 31, 2019, in our EHR (Epic Systems
Corporation) and the patients who received them. We did not
include prescriptions for buprenorphine or methadone as these
medications are used in medical assisted treatment (MAT) for
opioid use disorder [29]. We limited our analysis to only oral
capsule and tablet formulations (excluding oral liquid, buccal
films, patches, etc.).
Our interest was in the effect of our intervention on opioids
prescribed for acute pain. To this end, we excluded patients
with chronic pain from our analysis via a modified approach to
a validated algorithm [30]. Tian et al [30] achieved an accuracy
of 95% for the identification of patients with chronic diseases
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via (1) a single International Classification of Diseases, 9th
Revision (ICD-9) code [31] “highly likely” to represent chronic
pain OR (2) 2 or more ICD-9 codes “likely” to represent chronic
pain separated by at least 30 days OR (3) receipt of at least 90
days of opioids OR (4) an ICD-9 code “likely” to represent
chronic pain AND 2 or more pain scores greater than or equal
to 4.
We mapped ICD-9 codes utilized in the algorithm to the 10th
Revision (ICD-10) [32] using the Centers for Medicare and
Medicaid Services General Equivalence Mappings [33] via the
R package “touch” [34]. ICD code mappings were also manually
reviewed. There were 9476 prescriptions in our cohort that did
not include an ICD-10 and remained in our analysis as if they
did not meet criteria for exclusion. Our data set included
unreliable pain score documentation, so we eliminated this step
in the algorithm. Pain scores held the lowest positive predictive
value for identifying patients with chronic pain in the initial
study [30], and we presumed that excluding these patients would
only bias our results against our objective, as patients with
chronic pain are presumed to have long-term prescriptions.
Finally, we excluded all prescriptions written in the ED given
the results of our previous intervention.
Variables
Using our analytics software Qlik Sense (QlikTech
International), we identified all prescriptions for non-MAT
opioid medications written during the study period and extracted
a number of variables for each individual prescription and the
associated patient.
At the prescription level these variables were medication,
number of tablets, dosage unit (ie, mg), route of administration
(oral vs rectal), and frequency of administration. Using our
previously described method, we also included the calculated
duration of therapy [35]. We utilized this value to represent the
duration of the prescription as our prior work demonstrated that
what is documented in the prescription is at times unreliable
[35]. We also extracted precalculated MME/day for each
prescription. At the patient level we extracted demographic data
including age and sex.
Data Cleaning, Outcomes, and Statistical Analysis
In order to mitigate bias, all information was obtained through
the same data query, and all participants were selected in the
same way (eg, a script for an opioid medication). Participants
were retrospectively recruited from a continuous 24 months.
Participants were divided into 2 cohorts (12 months before and
after the intervention). The intervention was introduced on
August 24, 2018, so the month of August 2018 was included
in the preintervention cohort to avoid influencing
postintervention results.
We calculated and compared frequencies of missing values for
metrics of interest before and after the intervention.
Demographic information was compared to assess similarity
between the 2 cohorts.
The total number of prescriptions and unique patients were
evaluated before and after the intervention. To ensure our
intervention did not inadvertently cause an increase in the
frequency of opioid prescribing, we compared the median
number of prescriptions per patient per month as well as the
odds of a patient receiving more than 1 prescription or refills.
The proportion of prescriptions was calculated for each class
of opioid medication. Opioid class was determined by the active
ingredient in the compound. We chose not to separate by
schedule class as these can change [36,37]. We compared the
proportions of opioid classes before and after the intervention
and then measured if our intervention changed the quantity,
duration, or proportion of prescriptions greater than 90
MME/day for all prescriptions, as well as for each opioid class.
For statistical analysis, Wilcoxon rank-sum test was utilized for
nonparametric data, and t test for parametric data. Chi-square
and Fisher exact test were performed for comparison of
categorical values. Confidence intervals were included for all
appropriate analysis. Statistics were performed in R statistical
software (R Core Team).
Results
Overview of Prescriptions
There were 128,933 non-MAT opioid prescriptions written
during our study period. Of these, 103,338/128,933 (80.15%)
were written for oral tablet or capsule formulations. We
excluded 23,961/103,338 (23.19%) prescriptions that were
written for patients with chronic pain. Of the remaining 79,377,
we excluded 1131/79,377 prescriptions (1.42%) that were
written by the ED. The median duration for these ED
prescriptions was 2.7 days (IQR 2.5-3.3) with a median
dispensed quantity of 9 tablets (IQR 9-31).
The remaining 78,246 prescriptions were for 30,975 unique
patients. There were 38,976/78,246 (49.81%) prescriptions
written for 16,464/30,975 (53.15%) patients in the
preintervention period and 39,270/78,246 (50.19%) prescriptions
written for 17,399/30,975 (56.17%) patients in the
postintervention period. Figure 1 demonstrates the inclusion
and exclusion criteria leading to our study cohorts.
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Figure 1. Breakdown of our study cohort included excluded groups. ED: emergency department; MAT: medical assisted treatment.
Missing Data
Of the 78,246 prescriptions, 7167 (9.16%; 95% CI 8.96-9.36)
were missing a calculated duration. The proportion of missing
calculated durations decreased from 9.91% (7758/78,246; (95%
CI 9.62-1.02) to 8.41% (6578/78,246; 95% CI 8.14-8.70;
P<.001) before and after the intervention. In addition,
7156/78,246 (9.15%; 95% CI 8.94-9.35) prescriptions were
missing documented quantity dispensed with a reduction from
9.90% (7750/78,246; 95% CI 9.60-10.20) to 8.40%
(6570/78,246; 95% CI 8.13-8.68; P<.001) before versus after
the intervention. Finally, 1139/78,246 (1.46%; 95% CI
1.37-1.54) prescriptions were missing the MME/day field with
a significant increase in this proportion before versus after the
intervention (915/78,246 [1.17%; 95% CI 1.07-1.28] to
1358/78,246 [1.74%; 95% CI 1.61-1.87]; P<.001). Missing
values were excluded from their respective analysis.
Patient Demographics
Overall, 17,344/30,975 (55.99%; 95% CI 55.44%-56.55%) of
all unique patients were female. There was no significant
difference in patient sex before and after the intervention
(17,300/30,975 [55.85%; 95% CI 55.10%-56.61%] vs
17,237/30,975 [56.65%; 95% CI 55.91%-57.39%] female;
P=.14). The median age was 59, which did not change.
Rate of Prescribing
There was no significant change in the median number of
prescriptions written per month, before and after the intervention
(3254.5 [IQR 3176.25-3331.25] vs 3338 [3157.0-3391.5];
P=.59). The median monthly prescriptions per person remained
1 (IQR 1-2). The odds of getting more than 1 opioid prescription
after the intervention did not significantly increase (1.003, 95%
CI 0.967-1.04) and the odds of being prescribed a refill
decreased (0.801, 95% CI 0.747-0.858).
Types of Opioids Prescribed
The majority (48,261/78,246, 61.68%; 95% CI 61.34%-62.02%)
of prescriptions during the study period were for oxycodone.
Table 1 demonstrates the proportion of individual opioids.
There were small but significant reductions in the proportion
of prescriptions for morphine—6.30% (2456/38,976; 95% CI
6.06%-6.55%) to 5.95% (2335/39,270; 95% CI 5.72%-6.19%);
P=.04)—and oxymorphone—0.37% (143/38,976; 95% CI
0.31%-0.43%) to 0.24% (96/39,270; 95% CI 0.20%-0.30%;
P=.002). There was no change in the proportion of the other
opioids.
J Med Internet Res 2021 | vol. 23 | iss. 4 | e24360 | p. 4https://www.jmir.org/2021/4/e24360
(page number not for citation purposes)
Slovis et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Table 1. Proportion of each opioid during the study period with 95% confidence intervals.










aProportion of the number of that individual opioid prescriptions from the total 78,246 opioid prescriptions.
Dispensing and Duration
There was a significant reduction in the overall median quantity
of opioid tablets dispensed before versus after the intervention
(54 [IQR 40-120] vs 42 [IQR 18-90]; P<.001). There was also
a reduction in median duration of treatment before and after the
intervention (10.5 days [IQR 5.0-30] vs 7.5 days [IQR 3.0-30];
P<.001). Finally, there was a significant reduction in the
proportion of prescriptions greater than 90 MME/day (27.46%
[10,704/38,976; 95% CI 27.02%-27.91%] vs 22.86%
[8979/39,270; 95% CI 22.45%-23.28%]; P<.001), despite no
change in the median of 45 MME/day per prescription before
and after the intervention. These results are displayed in Figure
2.
There was a significant reduction in all metrics for oxycodone.
Tramadol and codeine demonstrated a reduction in tablets
dispensed, while codeine also had a reduction in the duration
of treatment (P<.001 for all three metrics). Hydromorphone had
a significant reduction (P<.001) in MME greater than 90/day
despite no change in the other metrics. Table 2 demonstrates
the effect of our intervention overall, and on each type of opioid
medication before and after the intervention.
Given the majority of prescriptions were for oxycodone, Figure
3 demonstrates monthly numbers of tablets dispensed, median
duration of treatment, and proportion of prescriptions greater
than 90 MME/day for oxycodone.
Figure 2. Monthly median tablets prescribed pre and post-intervention, monthly median duration (days) pre and post-intervention and proportion of
prescriptions >90 MME/day pre and post-intervention for all opioids. MME: morphine milligram equivalents.
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Table 2. Quantity, duration of treatment, and proportion of MMEa/day >90 for all opioids and each individual opioid before and after the intervention.
P valueAfter the interventionBefore the interventionOpioid
All opioids
<.00142 (18-90)54 (40-120)Quantity in tablets (IQR)
<.0017.5 (3.0-30)10.5 (5.0-30.0)Duration in days (IQR)
<.0018979/39,270 (22.86); 22.45-23.2810,704/38,976 (27.46); 27.02-27.91>90 MME/day, n/N (%); 95% CI
Codeine
<.00120 (18-42)42 (40-42)Quantity in tablets (IQR)
<.0012.5 (1.7-5.0)5 (5-7.5)Duration in days (IQR)
00>90 MME/day, n/N (%); 95% CI
Hydrocodone
.9145 (30-90)42 (36-51)Quantity in tablets (IQR)
.5311.25 (8.75-15.63)15 (11-22.5)Duration in days (IQR)
>.994/9 (44.44); 15.34-77.351/4 (25.00); 1.32-78.06>90 MME/day, n/N (%); 95% CI
Hydromorphone
60 (20-120)60 (42-120)Quantity in tablets (IQR)
7.5 (3.3-20)7.5 (5-20)Duration in days (IQR)
<.001664/2010 (33.03); 30.99-35.15783/1985 (39.45); 37.29-41.64>90 MME/day, n/N (%); 95% CI
Meperidine
.41100 (100-120)144 (60-182)Quantity in tablets (IQR)
.936 (6.0-10.5)10.5 (5.0-15.0)Duration in days (IQR)
00>90 MME/day, n/N (%); 95% CI
Morphine
60 (60-90)60 (56-90)Quantity in tablets (IQR)
30 (20-30)30 (30-30)Duration in days (IQR)
.871048/2335 (44.88); 42.85-46.931092/2456 (44.46); 42.49-46.46>90 MME/day, n/N (%); 95% CI
Oxycodone
<.00142 (18-90)56 (42-120)Quantity in tablets (IQR)
<.0016 (2.5-30)10 (5.0-30.0)Duration in days (IQR)
<.0017190/24,299 (29.59); 29.02-30.178722/23,962 (36.40); 35.79-37.01>90 MME/day, n/N (%); 95% CI
Oxymorphone
.1862 (60-90)60 (56-90)Quantity in tablets (IQR)
30 (30-30)30 (30-30)Duration in days (IQR)
>.9958/96 (60.42); 49.89-70.1085/143 (59.44); 50.90-67.47>90 MME/day, n/N (%); 95% CI
Tapentadol
.29101 (60-120)112 (60-166)Quantity in tablets (IQR)
30 (30-30)30 (30-30)Duration in days (IQR)
.2115/90 (16.67); 9.93-26.3221/82 (25.61); 16.89-36.65>90 MME/day, n/N (%); 95% CI
Tramadol
<.00130 (12-90)40 (28-97.5)Quantity in tablets (IQR)
10 (5-20)10 (7.5-20.0)Duration in days (IQR)
00>90 MME/day, n/N (%); 95% CI
aMME: morphine milligram equivalents.
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Figure 3. Monthly median number of tablets dispensed, median durations (days) of treatment and proportion of oxycodone prescriptions > 90 MME/day
pre and post-intervention. MME: morphine milligram equivalents.
Discussion
Principal Findings
In this quasi-experimental pre–post study our intervention
resulted in a significant reduction (P<.001) in the duration of
treatment, quantity of tablets dispensed, and proportion of
prescriptions greater than 90 MME/day for all opioid
prescriptions written for patients with acute pain without an
increase in the rate of prescribing or MME/day per prescription,
while maintaining clinician autonomy. Our postintervention
median duration of treatment for all opioids was 7.5 days, which
is slightly longer than the CDC’s recommendations of 7 days
[16], but an improvement over our preintervention duration of
10 days. In addition, we improved compliance with CDC
recommendations that opioid dosing should not exceed 90
MME/day [16].
Oxycodone accounted for more than 60% (48,261/78,246,
61.68%) of our institutions prescriptions and was the only opioid
to demonstrate reductions in all metrics, while tramadol,
codeine, and hydromorphone had reductions in at least one
metric. Our results show an improved median duration of
treatment for oxycodone of 6 days, which is within CDC’s
recommendations for acute pain.
Modifications to prescription presets is a relatively simple and
effective way to combat the opioid epidemic. Our results are
similar to other studies of single departments. Delgado et al
[23] studied 2 EDs prescribing oxycodone. They examined the
difference in prescribing patterns before and after the
implementation of a new EHR, where they previously had no
prescribing presets and the new EHR was preset to 10 tablets
per prescription demonstrating a decrease in the median number
of tablets from 11.3 and 12.6 to 10 and 10.9, respectively, in
the 2 departments [23].
Chiu et al [22] looked at opioid prescribing in the outpatient
surgical setting. Their study included 3 hospitals examining
changes in preset opioid prescription quantities from 30 to 12
tablets. The intervention reduced the median number of tablets
prescribed from 30 to 20, with a decrease of 5.22 tablets and
34.41 MME per prescription, and no difference in refill rates
[22].
Despite their expectation of decreased tablets dispensed, Zwank
et al [26] showed an increase from 15.31 to 15.77 in the mean
number of tablets dispensed for hydrocodone and oxycodone
in the ED after they removed a 15-tablet preset and required
manual entry of a dispense quantity [26]. This may suggest that
presets are vital to reduce prescribing quantities; however, this
is contradicted by Santistevan et al [24] who demonstrated that
removal of a default of 20 tablets for hydrocodone and
oxycodone reduced the median number of tablets prescribed
from 20 to 15, although their preintervention presets were higher
than Zwank et al’s.
Montoy et al [25] implemented a block-randomization study at
2 EDs. They examined 6 possible opioid tablet quantity presets:
“status quo” 12 and 20, as well as “null,” 5, 10, and 15. They
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demonstrated that each tablet increase in preset yielded an
increase of 0.19 tablets prescribed, and lower default quantities
were associated with lower number of pills in 8 of 15 pairwise
comparisons [25]. These results support our approach that
modifications to prescription presets are an effective way to
enact change in opioid prescribing.
Despite a number of publications demonstrating reductions in
opioid prescribing through presets [22,23,25], to our knowledge
this research is the first to demonstrate reduction in overall
opioid prescribing and prescribing of multiple individual opioids
for an entire hospital system. Our hospitals and ambulatory
clinics are located in one of the most lethal counties in one of
the most lethal states associated with the opioid epidemic
[38-40]. The CDC estimates that the risk of chronic use of
opioids is 13.5% after 8 days of treatment [15] and the World
Health Organization estimates the annual rate for
opioid-dependent individuals overdosing at 45% and death at
0.65% [41]. We reduced our median duration of treatment from
10.5 to 7.5 (6 days for oxycodone), thus potentially bringing
more than half of our institutions’ opioid prescriptions below
this high-risk threshold.
Examining our hospital’s nearly 3300 prescriptions per month
and postintervention median reduction of 12 tablets per
prescription, we can estimate that our hospital system has
reduced nearly 39,600 opioid tablets from being prescribed per
month, or 475,200 tablets per year. Extrapolate this to the over
168 million prescriptions written in the United States in 2018
[42], and our simple intervention could potentially reduce the
number of tablets being prescribed each year by over 2 billion.
Our intervention excluded prescriptions for chronic pain, thus
these approximations are likely extreme, but even a small
percentage of these estimates is a net large and clinically
important reduction in opioid tablets. Significant reductions in
the number of opioid tablets prescribed, durations of treatment,
and doses greater than 90 MME/day can play an important role
in curbing the epidemic, improving quality of care, and
ultimately saving lives.
Limitations
Our findings have a number of limitations. First, although a
validated algorithm, we did not complete Tian et al’s [30]
algorithmic approach to identifying patients with chronic pain
with EHR data. We believe this is unlikely to significantly bias
our results as this was the least sensitive element in the original
study and exclusion of this step, if anything, biases our results
away from our objective (ie, including more patients with
chronic pain with presumably higher doses and longer
prescription durations in our data set). In addition, this algorithm
was designed for use with ICD-9 codes. We mapped ICD-9 to
ICD-10 codes and performed a manual review, but errors may
still have persisted. Second, with regard to our results, we did
demonstrate that morphine and oxymorphone had slight
reductions in proportion prescribed after the intervention;
however, this was unlikely to have biased our results. We also
should acknowledge that 9.16% (7167/78,246) of our study
cohort were missing calculated durations and quantity of tablets
dispensed and the percentage of these missing values decreased
after the intervention, while 1.46% (1139/78,246) of
prescriptions were missing MME/day and this increased after
the intervention. We believe the majority of missing calculated
durations are likely due to the missing dispense quantities, which
are required for the computation of this metric. Missing
MME/day is likely due to missing concentrations, doses, or
conversion factors of some formulations. Some of these missing
values may be due to prescriptions being refilled and bypassing
some of the new requirements we implemented. We excluded
missing data from our analysis, but it is possible this exclusion
influenced our results.
For our MME/day threshold we chose to use the CDC guidelines
for opioid prescribing as the CDC is a federal agency that
upholds “the health of the people of the United States.” [43] It
should be noted that individual states may have opioid
prescribing guidelines that deviate from those presented by the
CDC [44].
It should also be noted that our research was a
quasi-experimental pre–post study, and we cannot infer causality
with our intervention and the results observed. It is possible that
other influential factors could have played a role in the reduction
of opioid prescribing at out institution during this 2-year period,
as the opioid epidemic has come to the forefront of modern
medicine. However, we believe our results are encouraging,
and other studies have demonstrated similar outcomes to suggest
our intervention likely played at least a role in the reduction of
prescribing patterns at our institution. Finally, our region has
one of the highest opioid overdose and death rates in the nation,
making our results of high value to curbing the epidemic;
however, our results may not be generalizable to the rest of the
country.
Conclusions
In this quasi-experimental retrospective pre–post analysis, we
demonstrated that modifications of the opioid prescribing presets
in our hospital system’s EHR can improve prescribing practice
patterns and reduce the number of pills dispensed, duration of
treatment, and proportion of prescriptions greater than 90
MME/day. We have identified a simple and effective way to
reduce opioid prescribing, and to our knowledge, we are the
first to perform this kind of an intervention throughout an entire
hospital system, and not just at the department level. Reduction
in opioid prescribing may aid in curbing the opioid epidemic,
thus improving quality of care and potentially saving lives.
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CDC: Centers for Disease Control and Prevention
CPOE: computerized provider order entry
ED: emergency department
EHR: electronic health record
ICD-9: International Classification of Diseases, 9th Revision
MAT: medical assisted treatment
MME: morphine milligram equivalents
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